dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Pozo Rosich, Patricia |
dc.contributor.author | Samaan, Karen |
dc.contributor.author | Schwedt, Todd J. |
dc.contributor.author | Nicholson, Robert A. |
dc.contributor.author | Rettiganti, Mallikarjuna |
dc.contributor.author | Pearlman, Eric M. |
dc.date.accessioned | 2022-06-13T12:59:16Z |
dc.date.available | 2022-06-13T12:59:16Z |
dc.date.issued | 2021-06 |
dc.identifier.citation | Pozo-Rosich P, Samaan KH, Schwedt TJ, Nicholson RA, Rettiganti M, Pearlman EM. Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis. Adv Ther. 2021 Jun;38:3154–3165. |
dc.identifier.issn | 1865-8652 |
dc.identifier.uri | https://hdl.handle.net/11351/7671 |
dc.description | Eficàcia; Galcanezumab; Migranya |
dc.description.sponsorship | This study (design and conduct of the study; collection, management, analysis, and interpretation of the data, preparation of the manuscript, and decision to submit the manuscript for publication) was funded by Eli Lilly and Company, Indianapolis, IN, USA. The journal’s Rapid Service and Open Access Fees are also funded by the study sponsor (Eli Lilly and Company, Indianapolis, IN, USA). |
dc.language.iso | eng |
dc.publisher | Springer |
dc.relation.ispartofseries | Advances in Therapy;38 |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Migranya - Tractament |
dc.subject | Anticossos monoclonals - Ús terapèutic - Eficàcia |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject.mesh | Migraine Disorders |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antibodies, Monoclonal, Humanized |
dc.subject.mesh | Treatment Outcome |
dc.title | Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1007/s12325-021-01708-8 |
dc.subject.decs | trastornos migrañosos |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | anticuerpos monoclonales humanizados |
dc.subject.decs | resultado del tratamiento |
dc.relation.publishversion | https://doi.org/10.1007/s12325-021-01708-8 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Pozo-Rosich P] Unitat de Cefalea, Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca en Cefalea i Dolor Neurològic, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Samaan KH] Eli Lilly and Company, LTC-South, Indianapolis, IN, USA. [Schwedt TJ] Mayo Clinic, Scottsdale, AZ, USA. [Nicholson RA, Rettiganti M, Pearlman EM] Eli Lilly and Company, LTC-South, Indianapolis, IN, USA |
dc.identifier.pmid | 33950375 |
dc.identifier.wos | 000647518100002 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |